Speakers

Bill Donaldson is CEO at Estrigenix. Dr. Donaldson has more than 35 years of experience in organic synthesis and chemical methodology development as a faculty member at Marquette University. It was there that his team lead the discovery of a family of highly selective ERbeta agonists upon which Estrigenix was formed. Bill retired from Marquette in May 2021 to lead Estrigenix Therapeutics full time. He has been the principal investigator on numerous grants from the National Science Foundation and the National Institute of Health. Previous experience includes serving as chair of the NIH National Research Service Award Study Section (2014-2017), as associate dean in the College of Arts and Sciences at Marquette University (2010-2014), and as chairperson of the Milwaukee Section of the American Chemical Society (2006-2009).